ITCI - イントラセルラ―・セラピ―ズ (Intra-Cellular Therapies Inc.) イントラセルラ―・セラピ―ズ

 ITCIのチャート


 ITCIの企業情報

symbol ITCI
会社名 Intra-Cellular Therapies Inc (イントラセルラ―・セラピ―ズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 イントラ・セルラー・セラピーズ(Intra-Cellular Therapies Inc.)はバイオ医薬品会社である。同社は中枢神経系(CNS)内の細胞内シグナル伝達機構を標的とすることにより、神経精神医学的および神経学的障害における不十分な医学的ニーズに対処する小分子薬物の発見・臨床開発を行う。同社は神経学的および精神医学的障害の治療のための薬物を発見・開発する。ルマテペロン(ITI-007)は、主要製品候補である。同社の双極性うつ病プログラムは、2つの第III相多施設、無作為化、二重盲検、プラセボ対照臨床試験で構成される。1つは単独治療としてルテテペロンを評価し、もう1つはリチウムまたはバルプロエートによる補助療法としてルテテペロンを評価する。同社は、アルツハイマー病(AD)を含む認知症患者の激越の治療のためのルテテペロンの第III相開発を開始した。   イントラセルラ―・セラピ―ズは、米国のバイオ製薬企業。中枢神経系内の細胞内シグナル伝達機構を標的とする神経精神障害および神経障害に対処する小分子薬の発見と臨床開発に焦点を当てる。主要製品候補は、統合失調症のためのファ―ストインクラスの治療薬「ITI-007」、統合失調症および認知障害の治療薬「 ITI-002」がある。   Intra-Cellular Therapies, Inc. is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Its lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. The company also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease, and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates on August 29, 2013 and is headquartered in New York, NY.
本社所在地 430 East 29th Street New York NY 10016 USA
代表者氏名 Lawrence J. Hineline ローレンスJ.ヒネリン
代表者役職名 Chief Financial Officer Vice President - Finance Treasurer Assistant Secretary
電話番号 +1 212-923-3344
設立年月日 41122
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 49人
url www.intracellulartherapies.com
nasdaq_url https://www.nasdaq.com/symbol/itci
adr_tso
EBITDA EBITDA(百万ドル) -132.42960
終値(lastsale) 18.42
時価総額(marketcap) 1007744790.24
時価総額 時価総額(百万ドル) 996.25590
売上高 売上高(百万ドル) 0.03581
企業価値(EV) 企業価値(EV)(百万ドル) 592.49140
当期純利益 当期純利益(百万ドル) -127.03560
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Intra-Cellular Therapies Inc revenues decreased from $210K to $0K. Net loss increased 63% to $72.9M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase of 91% to $59.3M (expense) General and administrative - Balancing v increase of 20% to $8.3M (expense).

 ITCIのテクニカル分析


 ITCIのニュース

   Intra-Cellular, Qorvo rise; Slack, Tiffany fall  2020/09/09 20:38:48 ABC News
Stocks that moved heavily or traded substantially Wednesday: Intra-Cellular, Qorvo rise; Slack, Tiffany fall
   Implied Volatility Surging for Intra-Cellular Therapies (ITCI) Stock Options  2020/06/04 12:49:00 Zacks Investment Research
Investors need to pay close attention to Intra-Cellular Therapies (ITCI) stock based on the movements in the options market lately.
   Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Misses Revenue Estimates  2020/05/07 15:05:04 Zacks Investment Research
Intra-Cellular (ITCI) delivered earnings and revenue surprises of 25.51% and -38.11%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   What Awaits Intra-Cellular Therapies (ITCI) in Q4 Earnings?  2020/02/18 15:13:00 Zacks Investment Research
Intra-Cellular Therapies (ITCI) is likely to provide update on its commercialization plan for Caplyta, approved for treating schizophrenia in December 2019, on the Q4 call.
   Intra-Cellular Sinks on Large Share Offering  2020/01/07 15:00:15 Baystreet.ca
Intra-Cellular Therapies Inc (NASDAQ:ITCI) reported a proposed public offering of 10,000,000 shares of common stock. The New York-based Intra-Cellular is a biopharmaceutical company founded on Nobel prize-winning research that allows it to understand …
   What Awaits Intra-Cellular Therapies (ITCI) in Q4 Earnings?  2020/02/18 15:13:00 Zacks Investment Research
Intra-Cellular Therapies (ITCI) is likely to provide update on its commercialization plan for Caplyta, approved for treating schizophrenia in December 2019, on the Q4 call.
   Intra-Cellular Sinks on Large Share Offering  2020/01/07 15:00:15 Baystreet.ca
Intra-Cellular Therapies Inc (NASDAQ:ITCI) reported a proposed public offering of 10,000,000 shares of common stock. The New York-based Intra-Cellular is a biopharmaceutical company founded on Nobel prize-winning research that allows it to understand …
   The Daily Biotech Pulse: Xeris Jumps On Positive Data, Mixed Results For Merck's Keytruda-Chemo Combo In Lung Cancer, Intra-Cellular Announces Offering  2020/01/07 12:57:46 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 6.) Agile Therapeutics Inc (NASDAQ: AGRX ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Audentes Therapeutics Inc (NASDAQ: BOLD ) BioNTech SE – ADR (NASDAQ: BNTX ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Inspire Medical Systems Inc (NYSE: INSP ) Nevro Corp (NYSE: NVRO ) Nymox Pharmaceutical Corp (NASDAQ: NYMX ) (announced publication of a peer reviewed research report on the experimental studies for its fexapotide triflutate treatment for prostate enlargement and low-grade prostate cancer) Orthopediatrics Corp (NASDAQ: KIDS ) (announced sale of its adult Vilex business in Tennessee to Squadron Capital and used the proceeds for the repayment of term loan due to Squadron) Oyster Point Pharma Inc (NASDAQ: OYST ) Sanofi SA (NASDAQ: SNY ) (JPMorgan upgraded the shares from Neutral to Overweight, citing an attractive valuation) Soligenix, Inc.
   5 Stocks To Watch For January 7, 2020  2020/01/07 09:14:07 Benzinga Feeds
Some of the stocks that may grab investor focus today are: Wall Street expects AngioDynamics, Inc. (NASDAQ: ANGO ) to report quarterly earnings at $0.02 per share on revenue of $71.28 million before the opening bell. AngioDynamics shares gained 3.4% to $17.48 in after-hours trading. Intra-Cellular Therapies Inc (NASDAQ: ITCI ) reported a proposed public offering of 10,000,000 shares of common stock. Intra-Cellular Therapies shares dropped 3.5% to $29.55 in the after-hours trading session. Analysts expect Northern Technologies International Corporation (NASDAQ: NTIC ) to report quarterly earnings at $0.13 per share on revenue of … Full story available on Benzinga.com
   Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus  2019/12/29 23:38:06 Benzinga
Biotech stocks advanced in the penultimate week of the year, and the iShares NASDAQ Biotechnology Index (NASDAQ: IBB ) is on track to end the year with gains in excess of 25%. The previous week saw FDA announcements on verdicts for several therapeutic options. Notable among the therapeutic options that crossed the FDA hurdle were Allergan plc (NYSE: AGN )'s migraine drug; Flexion Therapeutics Inc (NASDAQ: FLXN )'s Zilretta, which was given a label expansion; Intra-Cellular Therapies Inc (NASDAQ: ITCI )'s schizophrenia drug; and two generics for Eliquis, a blood thinner marketed by Bristol-Myers Squibb Co (NYSE: BMY ) and Pfizer Inc. (NYSE: PFE ). However, Correvio Pharma Corp (NASDAQ: CORV )'s Brinavess, a drug to treat atrial fibrillation, stumbled at the FDA altar. A big gene therapy collaboration agreement between Roche Holdings AG Basel ADR (OTC: RHHBY ) and Sarepta Therapeutics Inc (NASDAQ: SRPT ) was announced. The following are key biotech catalysts for the unfolding week: PDUFA Dates The FDA is scheduled to rule on the pancreatic cancer drug candidate lynparza, which is being co-developed by AstraZeneca plc (NYSE: AZN ) and Merck & Co., Inc. (NYSE: MRK ).
   Intra-Cellular Sinks on Large Share Offering  2020/01/07 15:00:15 Baystreet.ca
Intra-Cellular Therapies Inc (NASDAQ:ITCI) reported a proposed public offering of 10,000,000 shares of common stock. The New York-based Intra-Cellular is a biopharmaceutical company founded on Nobel prize-winning research that allows it to understand …
   The Daily Biotech Pulse: Xeris Jumps On Positive Data, Mixed Results For Merck's Keytruda-Chemo Combo In Lung Cancer, Intra-Cellular Announces Offering  2020/01/07 12:57:46 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 6.) Agile Therapeutics Inc (NASDAQ: AGRX ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Audentes Therapeutics Inc (NASDAQ: BOLD ) BioNTech SE – ADR (NASDAQ: BNTX ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Inspire Medical Systems Inc (NYSE: INSP ) Nevro Corp (NYSE: NVRO ) Nymox Pharmaceutical Corp (NASDAQ: NYMX ) (announced publication of a peer reviewed research report on the experimental studies for its fexapotide triflutate treatment for prostate enlargement and low-grade prostate cancer) Orthopediatrics Corp (NASDAQ: KIDS ) (announced sale of its adult Vilex business in Tennessee to Squadron Capital and used the proceeds for the repayment of term loan due to Squadron) Oyster Point Pharma Inc (NASDAQ: OYST ) Sanofi SA (NASDAQ: SNY ) (JPMorgan upgraded the shares from Neutral to Overweight, citing an attractive valuation) Soligenix, Inc.
   5 Stocks To Watch For January 7, 2020  2020/01/07 09:14:07 Benzinga Feeds
Some of the stocks that may grab investor focus today are: Wall Street expects AngioDynamics, Inc. (NASDAQ: ANGO ) to report quarterly earnings at $0.02 per share on revenue of $71.28 million before the opening bell. AngioDynamics shares gained 3.4% to $17.48 in after-hours trading. Intra-Cellular Therapies Inc (NASDAQ: ITCI ) reported a proposed public offering of 10,000,000 shares of common stock. Intra-Cellular Therapies shares dropped 3.5% to $29.55 in the after-hours trading session. Analysts expect Northern Technologies International Corporation (NASDAQ: NTIC ) to report quarterly earnings at $0.13 per share on revenue of … Full story available on Benzinga.com
   Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus  2019/12/29 23:38:06 Benzinga
Biotech stocks advanced in the penultimate week of the year, and the iShares NASDAQ Biotechnology Index (NASDAQ: IBB ) is on track to end the year with gains in excess of 25%. The previous week saw FDA announcements on verdicts for several therapeutic options. Notable among the therapeutic options that crossed the FDA hurdle were Allergan plc (NYSE: AGN )'s migraine drug; Flexion Therapeutics Inc (NASDAQ: FLXN )'s Zilretta, which was given a label expansion; Intra-Cellular Therapies Inc (NASDAQ: ITCI )'s schizophrenia drug; and two generics for Eliquis, a blood thinner marketed by Bristol-Myers Squibb Co (NYSE: BMY ) and Pfizer Inc. (NYSE: PFE ). However, Correvio Pharma Corp (NASDAQ: CORV )'s Brinavess, a drug to treat atrial fibrillation, stumbled at the FDA altar. A big gene therapy collaboration agreement between Roche Holdings AG Basel ADR (OTC: RHHBY ) and Sarepta Therapeutics Inc (NASDAQ: SRPT ) was announced. The following are key biotech catalysts for the unfolding week: PDUFA Dates The FDA is scheduled to rule on the pancreatic cancer drug candidate lynparza, which is being co-developed by AstraZeneca plc (NYSE: AZN ) and Merck & Co., Inc. (NYSE: MRK ).
   Investors flock to neuro drug makers after FDA approves new schizophrenia drug  2019/12/23 19:47:00 MarketWatch
The approval of Intra-Cellular Therapies Inc.’s schizophrenia drug Caplyta on Monday is the latest indicator that some drug developers are finally…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 イントラセルラ―・セラピ―ズ ITCI Intra-Cellular Therapies Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)